Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30

Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol (1984) 5.65

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.09

Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology (2007) 3.85

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol (2009) 3.46

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology (2010) 3.08

Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology (2007) 3.08

Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes (1998) 2.93

Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology (2014) 2.74

Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res (2008) 2.69

Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther (2008) 2.59

The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol (2008) 2.24

Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro. Retina (2015) 2.03

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol (1999) 1.90

Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) (2006) 1.73

Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol (2012) 1.49

Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology (1999) 1.32

Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun (2011) 1.03

Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina (2011) 0.94

A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol (2015) 0.93

Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting. Curr Eye Res (2012) 0.86

Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. Ophthalmologica (2011) 0.81